Matthew Bick
Matthew Bick is CEO and co-founder at Accipiter Biosciences. Previously, he served as Senior Director of Protein Sciences at Neoleukin Therapeutics and held senior scientist roles at Lyell Immunopharma and the University of Washington.
Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline
Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.
Seattle’s Accipiter Bio Raises $12.7M, Partners with Pfizer and Kite Pharma to Advance AI-Designed Multi-Target Protein Therapies
Seattle biotech startup Accipiter Biosciences, founded by researchers from Nobel laureate David Baker's lab, secured $12.7 million and partnerships with Pfizer and Kite Pharma to develop AI-designed multi-target proteins aiming to improve disease treatment efficacy and reduce clinical trial costs.
Organizations
See all 10-
Accipiter Biosciences co-founder and Chief Executive Officer 2023–present, Chief Executive Officer, CSO 2023 · current
-
Neoleukin Therapeutics Senior Director of Protein Sciences 2023, Director of Protein Sciences 2021–2023, Principal Scientist 2020–2021 · past
-
Lyell Immunopharma Senior Scientist / Project Lead 2019–2020 · past
Education
-
The Rockefeller University PhD, Biophysics · 2003–2010
-
University of Rochester BS, Microbiology · 1995–2000
-
University of North Carolina School of the Arts High School Diploma, Classical Guitar Performance, Composition · 1991–1995